Spruce Biosciences, Inc.
A clinical-stage biopharmaceutical company developing drug therapies for rare endocrine (hormone) disorders. Its lead experimental medicine, tildacerfont, is being studied for people living with congenital adrenal hyperplasia, a rare genetic condition that disrupts the body's hormone production. Founded in 2013 and based in South San Francisco, the company went public on the US stock market in 2021.
| Holder | Schedule | % of class | Shares | Filed |
|---|---|---|---|---|
| AWM Investment Company, Inc. | 13GPassive | 5.1% | 147.0K | Aug 14, 2026 |
| OrbiMed Advisors LLC | 13GPassive | 4.8% | 132.2K | Aug 14, 2026 |
| OrbiMed Capital LLC | 13GPassive | 2.5% | 67.8K | Aug 14, 2026 |
| ADAR1 Capital Management, LLC | 13G/APassive | 2.5% | 67.7K | Aug 14, 2026 |
| Daniel Schneeberger | 13G/APassive | 2.5% | 67.7K | Aug 14, 2026 |
| Kenneth Griffin | 13G/APassive | 1.9% | 51.9K | Aug 14, 2026 |
| Citadel Advisors LLC | 13G/APassive | 1.7% | 47.0K | Aug 14, 2026 |
| Citadel Advisors Holdings LP | 13G/APassive | 1.7% | 47.0K | Aug 14, 2026 |
| Citadel GP LLC | 13G/APassive | 1.7% | 47.0K | Aug 14, 2026 |
| Citadel Securities Group LP | 13G/APassive | 0.2% | 5.0K | Aug 14, 2026 |